Filing Flows

Filing Flows › Companies › Entera Bio › Cash flow

Entera Bio cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$7.4M in Q3 2026 · −$15.8M over twelve months

Operating cash flow−$7.4M
Capital spending−$21K
Free cash flow−$7.4M

Analysis

In Q3 2026, Entera Bio generated −$7.4M of operating cash flow and spent $21K on capital projects, leaving free cash flow of −$7.4M. That is $4.9M less than in Q3 2025 (−$2.5M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$15.8M; the largest uses were operating cash flow ($15.8M), capital spending ($51K); besides operations, cash came from other financing ($272M); the cash balance rose by $256M.

Operating cash flow was −$7.4M against net income of −$15.6M. The largest differences: other non-cash +$7.5M, prepaid and other assets −$3.6M, stock-based pay +$1.8M.

Free cash flow

Entera Bio: free cash flow by quarterEntera Bio: free cash flow by quarter−$1.5MQ4 2024−$1.4MQ1 2025−$1.7MQ2 2025−$2.5MQ3 2025−$1.9MQ4 2025−$3.1MQ1 2026−$3.5MQ2 2026−$7.4MQ3 2026
Operating cash flow less capital spending.
Entera Bio: operating cash flow against capital spendingEntera Bio: operating cash flow against capital spendingOperating cash flowCapital spending−$1.5M$3KQ4 2024−$1.4M$8KQ1 2025−$1.6M$29KQ2 2025−$2.5M$43KQ3 2025−$1.8M$27KQ4 2025−$3.1M$0Q1 2026−$3.5M$3KQ2 2026−$7.4M$21KQ3 2026
Latest (Q3 2026): Operating cash flow −$7.4M, Capital spending $21K.

Capital allocation, year by year

Entera Bio: where the cash came from (up) and went (down), by fiscal yearEntera Bio: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow −$9.1MFY2021: Shares issued $21.8MFY2021: Capital spending −$17K$21.8MFY2021FY2022: Operating cash flow −$12.5MFY2022: Shares issued $13KFY2022: Capital spending −$47K$13KFY2022FY2023: Operating cash flow −$7.3MFY2023: Shares issued $5KFY2023: Capital spending −$17K$5KFY2023FY2024: Operating cash flow −$6.8MFY2024: Shares issued $4.7MFY2024: Capital spending −$3K$4.7MFY2024FY2025: Operating cash flow −$7.4MFY2025: Shares issued $6.3MFY2025: Capital spending −$107K$6.3MFY2025
Over these 5 years operating cash flow totalled −$43.1M; the largest uses were operating cash flow ($43.1M) and capital spending ($191K). Cash-flow statements as filed.

Where the cash came from and went

Entera Bio: sources (+) and uses (−) of cash, Q3 2026Entera Bio: sources (+) and uses (−) of cash, Q3 2026Other financing$261MCash drawn (+) / kept (−)−$254MOperating cash flow−$7.4MCapital spending−$21KExchange rates−$5K
Entera Bio: sources (+) and uses (−) of cash, TTM to Q3 2026Entera Bio: sources (+) and uses (−) of cash, TTM to Q3 2026Other financing$272MCash drawn (+) / kept (−)−$256MOperating cash flow−$15.8MCapital spending−$51KExchange rates−$49K

From profit to cash

Entera Bio: net income to operating cash flow, Q3 2026Entera Bio: net income to operating cash flow, Q3 2026Net income−$15.6MDepreciation & amortization$9KStock-based pay$1.8MOther non-cash$7.5MPayables−$169KAccrued liabilities$617KPrepaid and other assets−$3.6MOperating cash flow−$7.4M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q1 2025270—285-15
Q4 202494—177-83

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$7.4M−$21K—−$254M−$7.4M
Q2 2026−$3.5M−$3K—−$6.5M−$3.5M
Q1 2026−$3.1M—$130K$3.0M−$3.1M
Q4 2025−$1.8M−$27K—$1.8M−$1.9M
Q3 2025−$2.5M−$43K$71K$2.3M−$2.5M
Q2 2025−$1.6M−$29K—$1.7M−$1.7M
Q1 2025−$1.4M−$8K$6.2M−$11.9M−$1.4M
Q4 2024−$1.5M−$3K$3.5M−$1.7M−$1.5M

Entera Bio: income statement and cash flow

Entera Bio, Q1 2025: revenue $42K. The chart follows the revenue to costs, profit and cash.

Entera Bio: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.